Jump to content

BI 224436: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Sebotic (talk | contribs)
fixed structure and chem identifiers, removed image with incorrect structure
Line 1: Line 1:
{{Drugbox
{{Drugbox
| IUPAC_name = (2''S'')-[4-(3,4-Dihydro-2''H''-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid
| IUPAC_name = (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid
| image = BI 224436.svg
| image =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number =
| CAS_number = 1155419-89-8
| PubChem =
| PubChem = 66561902
| DrugBank =
| DrugBank =
| ChemSpiderID = 27289461
| ChemSpiderID = 32698770
| UNII = 99A996378Y
| ATCvet =
| ATCvet =
| ATC_prefix = none
| ATC_prefix = none
Line 13: Line 14:
<!--Chemical data-->
<!--Chemical data-->
| C=24 | H=25 | N=1 | O=4
| C=24 | H=25 | N=1 | O=4
| molecular_weight = 391.460 g/mol
| molecular_weight = 442.515 g/mol
| smiles = CC(C)(C)O[C@@H](c1cnc2ccccc2c1c3ccc4c(c3)CCCO4)C(=O)O
| smiles = CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4
| StdInChI = 1S/C24H25NO4/c1-24(2,3)29-22(23(26)27)18-14-25-19-9-5-4-8-17(19)21(18)16-10-11-20-15(13-16)7-6-12-28-20/h4-5,8-11,13-14,22H,6-7,12H2,1-3H3,(H,26,27)/t22-/m0/s1
| StdInChI = 1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1
| StdInChIKey = DMWVBLFYARRIDL-QFIPXVFZSA-N
| StdInChIKey = MIXIIJCBELCMCZ-VWLOTQADSA-N


<!--Clinical data-->
<!--Clinical data-->

Revision as of 21:09, 30 August 2017

BI 224436
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life7 hrs (simulated)[1]
Identifiers
  • (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H25NO4
Molar mass442.515 g/mol g·mol−1
3D model (JSmol)
  • CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4
  • InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1
  • Key:MIXIIJCBELCMCZ-VWLOTQADSA-N

BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]

References